ArticleOrphanet journal of rare diseases2026
The Valdivia Project: genetic characterization of a unique Wolfram Syndrome cluster in coastal Ecuador.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to document the first genetically confirmed cases of WS1 in Ecuador. DESIGN AND
methodsA Cross-Sectional study was conducted among individuals with early-onset insulin-dependent diabetes, residing in Santa Elena Province, Ecuador. A detailed clinical history and family tree were obtained along with laboratory and imaging diagnostics. A genetic whole exome sequencing was performed to confirm WS1 or not (NWS).
resultsThis Ecuadorian cohort included 38 participants (19 males) aged < 35 years with an average diabetes onset at 3 years old. Approximately 50% of the patients are related by consanguinity. Genetic studies tested positive for WS1 in 26 (69%) patients, which yields a prevalence of 1/12,000 inhabitants and the presence of two previously undescribed variants located in exon 8. Twenty-three were homozygous. Positive antibody testing was reported in 3/26 WS1 and in 4/11 NWS patients. High prevalence of severe and early neurological complications: optic atrophy, deafness and urinary disorders were documented. No patient had diabetes insipidus.
conclusionsFindings suggest the highest WS1 prevalence worldwide and two novel WS1 variants. There is high consanguinity and frequency of severe, early clinical complications among WS1 patients. In addition, only 11% were diagnosed with type 1 diabetes, suggesting that younger patients with early-onset, non-autoimmune diabetes should undergo comprehensive genetic testing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.